MT-104 / MabTics - LARVOL DELTA

Drug Development. (PubMed, Alzheimers Dement) - "MT104 improved memory performance and global cognition in patients with MCI without safety concerns. These findings support the potential of dietary therapeutic strategies to reduce the risk of progression from MCI to AD dementia. Further studies are needed to confirm these results and explore the long-term benefits of MT104."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MT104, A Dietary Supplement Based on Cuscuta Seeds and Heat-Killed Probiotics, on Cognitive Function in Patients with Mild Cognitive Impairment: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. (PubMed, J Med Food) - "In addition, no significant findings were identified. This study highlighted the potential of dietary therapeutic strategies focused on reducing the risk of progression from MCI to AD."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders